NASDAQ$INGN

Inogen Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Inogen's revenue increased driven by sustained demand, improved average selling prices, and reduced impact of the COVID-19 pandemic.

Inogen's total revenue for Q3 2021 increased by 25.3% to $93.1 million compared to the same period in 2020. The increase was primarily driven by sustained demand, improved average selling prices, and the reduced impact of the COVID-19 pandemic. The company reported a net income of $12.2 million, or $0.53 per diluted share.

  • Total revenue reached $93.1 million, a 25.3% increase from Q3 2020.
  • Domestic direct-to-consumer revenue grew by 24.6% to $36.3 million compared to Q3 2020.
  • Rental revenue increased by 61.3% to $12.1 million compared to the same period in 2020.
  • The company signed an agreement with Ashfield Healthcare, LLC to enhance its go-to-market capabilities.

Headline financials

Total Revenue

$93.1M

Previous: $74.3M+25.3%
EPS (adj)

$0.53

Previous: -$0.08+762.5%
Capital Expenditures

-$4.81M

Previous: -$3.35M-43.4%
Free Cash Flow

$7.37M

Previous: -$5.05M+245.9%
Net Income

$12.2M

Previous: -$1.7M+816.5%
Operating Income

$6.37M

Previous: -$1.97M+423.1%
Gross Profit

$47.7M

Previous: $33M+44.5%
Cash & Equivalents

$242M

Previous: $214M+12.9%
Total Assets

$513M

Previous: $460M+11.4%
Stock-Based Comp

$2.79M

Previous: $2.05M+36.2%

Revenue & EPS history

Inogen · Revenue · Quarterly

$93.1M

Q3 2021+25.3%vs Q3 2020
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

Due to the expected supply chain constraints impacting semiconductor chip supply, the Company expects total revenue in the fourth quarter of 2021 to be similar to revenue in the fourth quarter of 2020. The Company expects negative Adjusted EBITDA and operating and net losses in the fourth quarter of 2021 and operating and net losses for full-year 2021, reflecting the anticipated supply-constrained revenue decline, increased cost of goods sold per unit, and higher operating expense in the period compared to the first nine months of 2021.

Tailwinds

  • The Company will continue to work with its manufacturing partners and explore other open-market avenues to procure necessary semiconductor chips.
  • The Company has made and plans to continue to make investments in clinical research
  • The Company has made and plans to continue to make investments in research and development
  • The Company has made and plans to continue to make investments in building the necessary infrastructure to support future revenue growth and predictability
  • The Company has made and plans to continue to make investments in margin expansion.

Headwinds

  • The company continues to see ongoing uncertainty in the business caused by supply chain disruptions.
  • The company continues to see ongoing uncertainty in the business caused by the increased cost of critical components
  • The company continues to see ongoing uncertainty in the business caused by the continued and varying impacts of the COVID-19 pandemic.
  • The Company expects increased cost of goods sold per unit in the fourth quarter of 2021 due to cost inflation of materials and labor throughout the supply chain, primarily related to semiconductor chips price increases.
  • As a result of the shortages, in the interim the Company expects to be supply constrained and unable to meet full customer demand for its products.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.7%

Avg return

Earnings day

-2.0%

Avg return

5 days after

-2.0%

Avg return

30 days after

49%

26 / 53 earnings

Positive

+35.5%

Q2 2024

Best reaction

-32.2%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.4%-5.3%-11.0%
Q4 2025+4.3%+5.8%+6.0%
Q3 2025-0.6%+0.9%-1.3%
Q1 2025-11.5%-14.4%-8.1%
Q4 2024-14.8%-14.6%-28.6%
Q3 2024+15.9%+9.1%-0.7%
Q2 2024+35.5%+50.6%+43.0%
Q1 2024+14.6%+17.7%+17.7%
Q4 2023-32.2%-24.3%-13.0%
Q3 2023-1.3%-8.1%+10.0%
Q2 2023-14.6%-18.7%-20.8%
Q1 2023-6.1%-19.3%-21.9%
Q4 2022-31.4%-32.4%-46.4%
Q3 2022-12.5%-10.0%-0.8%
Q2 2022-6.9%-7.3%-6.3%
Q1 2022-2.2%-7.8%+2.0%
Q4 2021+12.6%+25.3%+13.5%
Q3 2021-6.0%-7.3%-21.6%
Q2 2021-22.8%-16.8%-22.1%
Q1 2021-3.5%-2.4%-12.8%
Q4 2020+4.6%+5.4%-4.2%
Q3 2020-7.1%+9.8%+33.0%
Q2 2020+16.4%+17.0%-6.5%
Q1 2020-21.4%-20.1%-24.2%
Q4 2019+10.2%+5.4%+26.4%
Q3 2019+17.3%+19.7%+24.4%
Q2 2019-15.4%-18.5%-20.9%
Q1 2019-28.8%-22.2%-31.8%
Q4 2018-26.4%-25.9%-35.1%
Q3 2018-18.8%-22.6%-24.8%
Q2 2018+7.7%+6.3%+21.3%
Q1 2018+21.0%+18.7%+26.7%
Q4 2017-9.3%-8.4%-7.8%
Q3 2017+16.1%+12.9%+15.0%
Q2 2017-5.6%-3.9%+0.3%
Q1 2017+0.2%-2.6%+11.9%
Q4 2016+6.8%+6.0%+11.4%
Q3 2016+13.0%+15.8%+22.3%
Q2 2016+0.9%+9.3%+8.9%
Q1 2016-6.6%
Q4 2015+20.6%
Q3 2015-1.8%
Q2 2015+13.0%
Q1 2015+4.9%
Q4 2014+1.8%
Q4 2012+1.8%
Q3 2013-1.7%
Q3 2014+6.0%
Q2 2014+3.6%
Q2 2013+3.6%
Q1 2013+12.7%
Q1 2014+12.7%
Q4 2013-1.0%
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro